QUANTA-SYSTEM
31.1.2024 07:31:25 CET | Business Wire | Press release
Quanta System proudly opens the door to the New Year by unleashing the ultimate innovation in the picosecond laser technologies: Discovery PICO with VarioPulse Technology®. An unprecedented level of precision and versatility in a device that allows you to select the picosecond pulse-duration to personalize the treatments to meet the unique needs of each person.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130556983/en/
Pico Filling Treatment - skin rejuvenation (Photo: Business Wire)
Quanta System has always been committed to follow the evolving needs of the market and to listen and understand the needs of its customers. Discovery PICO VarioPulse Technology® represents a significant leap forward in the world of aesthetic medicine.
Featuring Pico Boost technology that can deliver up to 1.8GW of laser power perfectly controlled by the VarioPulse Technology®, this next-generation device welcomes you to 3 cutting-edge customized treatments that are precisely designed to perform tattoo removal and skin revitalization at their best.
Pico Tune-Ink, the adaptable treatment that removes tattoo ink of a wide variety of colour and complexity;
Pico Filling, the no down-time treatment that revitalizes the skin from within and improve its appearance;
Pico Plasma, the all round skin remodeling treatment that targets scars and acne scars.
Commenting on this major launch, Girolamo Lionetti, CEO of Quanta System, expresses his excitement, "We are thrilled to bring this new technology to the aesthetic world. Our primary goal of improving people's quality of life is greatly enhanced by continuing to work alongside our valued partners, the physicians, and providing patients with more and more customized treatments.”
This is just the first step of a new era laser roadmap focused on delivering the superior user experience and patient satisfaction that the market has been waiting for.
For more information about Discovery PICO VarioPulse Technology®, visit our website www.quantasystem.com or come to discover it in person at IMCAS Booth U322 Level 3 - February 1st -3rd 2024.
About Quanta System
For almost forty years Quanta System, a 100% Italian company distributed worldwide, is the reference point for the research, designing and manufacture of state-of-the-art laser systems for surgery, dermatology and aesthetic medicine and the conservation of art works.
In 2004 the company joins El.En. SpA, leader on the laser market listed on the Euronext STAR Milan ("STAR") of the Italian Stock Exchange and a partner of reference for health facilities, Institutions and Entities engaged in scientific and research projects at a global level.
Designed to be used by doctors, specialised operators and restorers, today the Quanta System lasers represent the "Gold Standard" thanks to a wide range of applications.
The laser systems are entirely manufactured in Italy: from Research & Development to production, the entire process takes place in the company's headquarters in Samarate (in the province of Varese).
Quanta System is a trusted partner, day in day out, of all doctors in every part of the world thanks to its ability to listen, its straightforward debates and the creation of new systems that increasingly meet the real needs of professionals so they can provide better care for their patients.
A constantly evolving company that has managed to update its production so that it has always managed to satisfy the developing needs of its time, without losing sight of its primary objective: contributing to the improvement of people's quality of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130556983/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom